NeonMind Biosciences Inc. (OTQBC: NMDBF) has announced advancements in its lead drug candidate, NEO-001, targeted at obesity management through high-dose psilocybin treatment combined with behavioral therapy. The company plans to hold a Pre-IND meeting with the FDA and a Pre-CTA Consultation in Canada in Q4 2021, with a Phase 1/2 study expected to start in 1H2022. NEO-001 aims to improve chronic weight management by addressing psychological and behavioral deficiencies inherent in current treatments, presenting opportunities for patients with comorbid conditions such as hypertension and diabetes.
NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) has launched its NeonMind branded functional mushroom coffee products in the United States as dietary supplements. The initial release features two ground coffee SKUs, with plans to introduce two instant coffee varieties shortly. NeonMind coffees utilize adaptogens and certified organic mushroom extracts, promoting benefits such as cognitive and immune support. The product launch adheres to FDA regulations, ensuring quality and safety. The global functional mushroom market is valued at $25.4 billion, projected to grow at 8.44% CAGR through 2026.